Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 13 | 2022 | 899 | 4.590 |
Why?
|
| Renin-Angiotensin System | 11 | 2021 | 182 | 3.850 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 72 | 3.590 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 77 | 3.580 |
Why?
|
| Premature Birth | 5 | 2022 | 38 | 2.500 |
Why?
|
| Peptidyl-Dipeptidase A | 5 | 2020 | 142 | 2.280 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 1007 | 1.430 |
Why?
|
| Kidney | 5 | 2022 | 485 | 1.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 87 | 1.330 |
Why?
|
| Adolescent | 16 | 2022 | 3248 | 1.300 |
Why?
|
| Peptide Fragments | 4 | 2019 | 420 | 1.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2020 | 134 | 1.210 |
Why?
|
| Infant, Premature | 4 | 2019 | 62 | 1.140 |
Why?
|
| Graft Rejection | 2 | 2017 | 149 | 1.060 |
Why?
|
| Humans | 38 | 2022 | 29013 | 1.040 |
Why?
|
| Pregnancy | 8 | 2022 | 807 | 1.040 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 148 | 1.030 |
Why?
|
| Child | 10 | 2022 | 2209 | 0.980 |
Why?
|
| Fetal Growth Retardation | 2 | 2022 | 17 | 0.970 |
Why?
|
| Blood Pressure | 6 | 2022 | 803 | 0.940 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 3 | 0.870 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 348 | 0.850 |
Why?
|
| Angiotensin I | 3 | 2019 | 262 | 0.850 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 52 | 0.840 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 9 | 0.830 |
Why?
|
| Male | 21 | 2022 | 17768 | 0.810 |
Why?
|
| Female | 21 | 2022 | 18114 | 0.810 |
Why?
|
| Disease Progression | 2 | 2020 | 572 | 0.790 |
Why?
|
| Infant, Newborn | 8 | 2022 | 595 | 0.760 |
Why?
|
| Purpura, Schoenlein-Henoch | 1 | 2019 | 3 | 0.720 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2019 | 47 | 0.710 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 162 | 0.710 |
Why?
|
| Continental Population Groups | 2 | 2019 | 221 | 0.700 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 266 | 0.680 |
Why?
|
| Food Supply | 1 | 2019 | 52 | 0.660 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 15 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 90 | 0.660 |
Why?
|
| Fetus | 1 | 2019 | 78 | 0.660 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 89 | 0.650 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 1353 | 0.650 |
Why?
|
| Health Status Disparities | 1 | 2019 | 107 | 0.640 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 133 | 0.640 |
Why?
|
| Child Behavior | 1 | 2017 | 25 | 0.630 |
Why?
|
| Complement C4b | 1 | 2017 | 2 | 0.630 |
Why?
|
| Nutritional Status | 1 | 2017 | 68 | 0.610 |
Why?
|
| Child, Preschool | 5 | 2022 | 1164 | 0.590 |
Why?
|
| Overweight | 1 | 2018 | 256 | 0.570 |
Why?
|
| Dietary Supplements | 1 | 2017 | 170 | 0.570 |
Why?
|
| Creatinine | 3 | 2022 | 173 | 0.570 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 192 | 0.560 |
Why?
|
| Hyperpigmentation | 1 | 2016 | 17 | 0.550 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 22 | 0.540 |
Why?
|
| Erythema | 1 | 2016 | 27 | 0.540 |
Why?
|
| Hot Temperature | 1 | 2016 | 71 | 0.540 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2015 | 6 | 0.540 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 15 | 0.540 |
Why?
|
| Transplants | 1 | 2015 | 22 | 0.540 |
Why?
|
| Isoantibodies | 1 | 2015 | 10 | 0.540 |
Why?
|
| Donor Selection | 1 | 2015 | 31 | 0.530 |
Why?
|
| HLA Antigens | 1 | 2015 | 35 | 0.520 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 338 | 0.490 |
Why?
|
| Pain | 1 | 2016 | 282 | 0.460 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2106 | 0.450 |
Why?
|
| Sex Factors | 3 | 2019 | 626 | 0.430 |
Why?
|
| Retrospective Studies | 8 | 2022 | 3107 | 0.430 |
Why?
|
| Nephrology | 2 | 2022 | 34 | 0.420 |
Why?
|
| Virus Internalization | 2 | 2020 | 6 | 0.380 |
Why?
|
| Obesity | 1 | 2017 | 1062 | 0.360 |
Why?
|
| Renin | 2 | 2021 | 112 | 0.330 |
Why?
|
| Risk Factors | 4 | 2020 | 3509 | 0.320 |
Why?
|
| Case-Control Studies | 2 | 2022 | 855 | 0.320 |
Why?
|
| Angiotensin II | 2 | 2018 | 279 | 0.280 |
Why?
|
| Prospective Studies | 2 | 2022 | 2010 | 0.270 |
Why?
|
| Renal Dialysis | 2 | 2018 | 259 | 0.270 |
Why?
|
| Body Mass Index | 2 | 2018 | 862 | 0.260 |
Why?
|
| Potassium | 2 | 2021 | 37 | 0.250 |
Why?
|
| Sodium | 2 | 2021 | 37 | 0.250 |
Why?
|
| Electronic Health Records | 2 | 2022 | 118 | 0.250 |
Why?
|
| Losartan | 1 | 2022 | 68 | 0.210 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 68 | 0.210 |
Why?
|
| Aldosterone | 1 | 2021 | 28 | 0.210 |
Why?
|
| Comorbidity | 2 | 2020 | 539 | 0.200 |
Why?
|
| Lung Injury | 1 | 2022 | 64 | 0.200 |
Why?
|
| Health Personnel | 1 | 2022 | 111 | 0.200 |
Why?
|
| Receptors, Virus | 1 | 2020 | 15 | 0.190 |
Why?
|
| Electrolytes | 1 | 2020 | 9 | 0.190 |
Why?
|
| Pediatrics | 1 | 2022 | 132 | 0.190 |
Why?
|
| Tunica Intima | 1 | 2020 | 59 | 0.190 |
Why?
|
| Rats, Inbred Lew | 1 | 2020 | 116 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2021 | 469 | 0.180 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 34 | 0.180 |
Why?
|
| Saliva | 1 | 2019 | 36 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 64 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2019 | 61 | 0.180 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 21 | 0.180 |
Why?
|
| Linear Models | 2 | 2017 | 425 | 0.180 |
Why?
|
| Proteinuria | 1 | 2019 | 57 | 0.180 |
Why?
|
| Prenatal Care | 1 | 2019 | 46 | 0.170 |
Why?
|
| Algorithms | 1 | 2022 | 461 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2019 | 32 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 636 | 0.170 |
Why?
|
| Physical Fitness | 1 | 2019 | 119 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3099 | 0.170 |
Why?
|
| Cardiovascular System | 1 | 2019 | 38 | 0.170 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 94 | 0.170 |
Why?
|
| Infant | 2 | 2022 | 967 | 0.170 |
Why?
|
| Logistic Models | 2 | 2017 | 725 | 0.160 |
Why?
|
| Angiotensins | 1 | 2018 | 49 | 0.160 |
Why?
|
| Placenta | 1 | 2019 | 63 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 189 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 385 | 0.160 |
Why?
|
| Animals | 2 | 2020 | 7297 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 17 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 286 | 0.150 |
Why?
|
| Prognosis | 2 | 2020 | 1362 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 784 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2022 | 1674 | 0.150 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 7 | 0.150 |
Why?
|
| Biopsy | 1 | 2017 | 241 | 0.140 |
Why?
|
| Gestational Age | 3 | 2022 | 95 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 273 | 0.140 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 14 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2018 | 345 | 0.140 |
Why?
|
| Rats | 1 | 2020 | 1604 | 0.140 |
Why?
|
| Complement Pathway, Classical | 1 | 2015 | 2 | 0.140 |
Why?
|
| Complement C1q | 1 | 2015 | 4 | 0.140 |
Why?
|
| Young Adult | 1 | 2022 | 2398 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 708 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 401 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2019 | 666 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2015 | 171 | 0.130 |
Why?
|
| Hospitalization | 3 | 2022 | 417 | 0.130 |
Why?
|
| United States | 2 | 2022 | 3604 | 0.120 |
Why?
|
| Exercise | 1 | 2019 | 587 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2020 | 1300 | 0.120 |
Why?
|
| North Carolina | 1 | 2018 | 1422 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2015 | 167 | 0.120 |
Why?
|
| Graft Survival | 1 | 2015 | 228 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 531 | 0.120 |
Why?
|
| Adult | 2 | 2022 | 8391 | 0.110 |
Why?
|
| Brain | 1 | 2019 | 930 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 518 | 0.100 |
Why?
|
| Exercise Test | 2 | 2019 | 194 | 0.080 |
Why?
|
| Birth Weight | 2 | 2019 | 38 | 0.080 |
Why?
|
| Privacy | 1 | 2022 | 9 | 0.060 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2022 | 27 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 26 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 32 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 111 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2022 | 440 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 113 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 168 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2022 | 501 | 0.050 |
Why?
|
| Chlorides | 1 | 2020 | 15 | 0.050 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 14 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 706 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 102 | 0.050 |
Why?
|
| Inpatients | 1 | 2020 | 64 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 110 | 0.040 |
Why?
|
| Calcium | 1 | 2020 | 296 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 29 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 892 | 0.040 |
Why?
|
| Uric Acid | 1 | 2017 | 24 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 863 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 1105 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 229 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2017 | 446 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 229 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 365 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1131 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1373 | 0.030 |
Why?
|
| Aged | 1 | 2022 | 9462 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 10805 | 0.020 |
Why?
|